Apigenin (4′,5,7-trihydroxyflavone) is one of the leading components supporting targeted treatment options. We explored the cytotoxic and apoptotic effects of various doses of apigenin administered alone and together with 5-fluorouracil (5-FU)—a chemotherapeutic agent with high cytotoxicity—for different incubation periods, on morphologic, DNA, RNA (messenger RNA [mRNA]), and protein levels on the p53 mutant HT29 human colon adenocarcinoma cell line. Treatment with apigenin alone for a 72-hour incubation at 90-μM dose resulted in an apoptotic percentage of 24.92% (P=.001). A higher percentage (29.13%) was observed after treatment with the same dose of apigenin plus 5-FU for the same incubation period (P=.001). These results were confirmed as mRNA and protein expression levels of caspase-3 increased 2.567-fold and mRNA expression levels of caspase-8 increased 3.689-fold compared with the control group. On the other hand, mRNA expression levels of mammalian target of rapamycin (mTOR) and cyclin D1 (CCND1) decreased by 0.423-fold and 0.231-fold, respectively. To our knowledge this is the first study showing that treatment with apigenin alone results in cell cycle arrest through activation of caspase cascade and stimulation of apoptosis in HT29 cells. It also shows that use of apigenin plus 5-FU further increases this effect. This study draws attention to the probable clinical effectiveness of apigenin plus a chemotherapeutic agent with high cytotoxicity. It also highlights the induction of desirable apoptotic effects by targeting the caspase cascade pathway through administration of reduced doses for shorter incubation periods.
The aim of the present study was to analyze the molecular mechanisms involved in blocking the signaling pathway and the effects of this on the progression of prostate cancer (CaP) cells in vitro. LNCaP human CaP cell line was stimulated with interleukin‑6 (IL‑6) in the presence/absence of Janus kinase (JAK) 2 (AG490), signal transducer and activator of transcription 3 [(STAT3) S3I‑201] inhibitors and tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL). Cytotoxic activity, the activation of phosphorylated (p)‑STAT3 protein, caspase (CASP) 3 activity at protein level, vascular endothelial growth factor (VEGF) A, VEGFC, vascular endothelial growth factor receptor 2, STAT3, matrix metalloproteinase-2, myeloid cell leukemia sequence 1 (MCL‑1), CASP8 and CASP9 messenger RNA (mRNA) levels were determined. Morphology and apoptosis were confirmed by DAPI staining and terminal deoxynucleotidyl transferase‑mediated dUTP nick‑end labeling (TUNEL) assay. IL‑6 rapidly induced the phosphorylation of STAT3 in a dose‑ and time‑dependent manner with a peak expression at 3 h at a concentration of 25 ng/ml. In addition, AG490 (50 µM) and S3I‑201 (300 µM) inhibited STAT3 activation. Western blotting results revealed that p‑STAT3 protein expression decreased significantly with AG490 and S3I‑201 treatment in LNCaP cells. AG490 and S3I‑201 induced the downregulation of VEGFA, MCL‑1 and STAT3 and the upregulation of CASP8 and CASP9 mRNA transcription levels. In addition, the inhibitors increased the level of CASP3 protein. Combinations of AG490‑ and S3I‑201‑TRAIL did not result in an increase in this effect. Parallel results were found by DAPI staining and TUNEL assay. To the best of our knowledge, this is the first study to investigate the possible clinical use of AG490 or S3I‑201, together with the reduced use of chemotherapeutic agents with high cytotoxicity, for their ability to exert an apoptotic effect, targeting the JAK/STAT3 pathway.
MicroRNAs (miRs) modulate the expression of target genes in the signal pathway on transcriptome level. The present study investigated the ‘epigenetic‑based miRNA (epi‑miRNA)‑mRNA’ regulatory network of miR‑34b, miR‑34c, miR‑148a, miR‑152, miR‑200a and miR‑200b epi‑miRNAs and their target genes, DNA methyltransferase (DNMT1, 3a and 3b), phosphate and tensin homolog (PTEN) and NK3 Homeobox 1 (NKX3.1), in prostate cancer (PCa) using reverse transcription‑quantitative PCR. The expression level of NKX3.1 were not significantly different between the PCa, Met‑PCa and control groups. However, in the PCa and Met‑PCa groups, the expression level of DNMT1 was upregulated, while DNMT3a, DNMT3b and PTEN were downregulated. Overexpression of DNMT1 (~5 and ~6‑fold increase in the PCa and Met‑PCa groups respectively) was accompanied by a decreased expression in PTEN, indicating a potential negative association. Both groups indicated that a high level of DNMT1 is associated with the aggressiveness of cancer, and there is a a directly proportional relationship between this gene and PSA, GS and TNM staging. A significant ~2 to ~5‑fold decrease in the expression levels of DNMT3a and DNMT3b was found in both groups. In the PCa group, significant associations were identified between miR‑34b and DNMT1/DNMT3b; between miR‑34c/miR‑148a and all target genes; between miR‑152 and DNMT1/DNMT3b and PTEN; and between miR‑200a/b and DNMT1. In the Met‑PCa group, miR‑148a, miR‑152 and miR‑200b exhibited a significant association with all target genes. A significant negative association was identified between PTEN and DNMT1 in the Met‑PCa group. It was also revealed that that miR‑148a, miR‑152 and miR‑200b increased the expression of DNMT1 and suppressed PTEN. Furthermore, the ‘epi‑miRNA‑mRNA’ bidirectional feedback loop was emphasised and the methylation pattern in PCa anti‑cancer therapeutics was highlighted.